Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association – GAA) document

Braido, Fulvio; Tiotiu, Angélica; Guidos, Guillermo; Baiardini, Ilaria; Cosini, Filippo; Sousa, Jaime Correia de; Bikov, András; Novakova, Sylvia; Labor, Marina; Кайдашев, Ігор Петрович; Nedeva, Denislava; Kowal, Krzysztof; Mihăicuţă, Ştefan; Pereira, Marilyn Urrutia; Solé, Dírceu; Novakova, Plamela; Chong-Neto, Herberto José; Vrzy, Laura; Ansotegui, Ignacio J.; Bernstein, Jonathan A.; Boulet, Louis‐Philippe; Canonica, Giorgio Walter; DuBuske, L.M.; Nunes, Carlos Pereira; Ivancevich, Juan Carlos; Santus, Pierachille; Emelyanov, Alexander; Steiropoulos, Paschalis

doi:10.1080/02770903.2021.2022160

Cited by 1 publication

(5 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Summarizing the existing evidence, it seems plausible to suggest the addition of a LAMA, for asthma symptom control, in patients with persistent asthma, uncontrolled with medium or high dose ICS + LABA treatment, either in a separate or the same inhaler device, which is more cost-effective [ 36 ]. Also, the use of a single triple inhaler simplifies the treatment in contrast to an open triple inhaler, and that fact could strengthen adherence.…”

Section: Discussionmentioning

confidence: 99%

“…As a result, the addition of a LAMA to the standard treatment with ICS + LABA probably reduces the risk of moderate and/or severe asthma exacerbations and should be used in cases wheredual treatment is inadequate in the prevention of the asthma exacerbations [ 21 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…To sum up, the addition of LAMA to the standard ICS + LABA treatment regimen undoubtedly significantly improves lung function in patients with inadequately controlled asthma [ 21 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…Currently, there are no reliable biomarkers that could identify patients with severe refractory asthma eligible for LAMA treatment initiation. Some asthma traits that might be predictive ofbetter response to treatment with LAMA could be a previous smoking history and fixed airway obstruction [ 36 ]. The role of other recognizable disease traits is still under investigation [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

“…Consequently, existing evidence suggests that the safety profile of adding LAMA to the standard treatment with ICS + LABA is excellent [ 36 ]. Table 1 presents the main characteristics of all studies included in this review.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma

Kotoulas

Tsiouprou

Domvri

et al. 2023

ARM

View full text Add to dashboard Cite

Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting β2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…To sum up, the addition of LAMA to the standard ICS + LABA treatment regimen undoubtedly significantly improves lung function in patients with inadequately controlled asthma [ 21 , 36 ].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations